Risks and complications in hip replacement are similar to
those associated with all joint replacements. They can include infection, dislocation, limb length inequality, loosening, impingement, osteolysis, metal sensitivity, nerve palsy, chronic pain and death.
Weight loss surgery before a hip replacement does not appear to change outcomes.
Edema appears around the hip in the hours or days following the surgery. This swelling is typically at its maximum 7 days after the operation, then decreases and disappears over the course of weeks. Only 5% of patients still have swelling 6 months after the operation.
Dislocation ,
eczema, redness and itching. Although little is known about the short- and long-term
pharmacodynamics and bioavailability of circulating metal degradation products
in vivo, there have been many reports of immunologic-type responses temporally associated with implantation of metal components. Individual case reports link immune hypersensitivity reactions with adverse performance of metallic cardiovascular, orthopedic and plastic surgical and dental implants. Some people with these prostheses experienced similar reactions to the metal debris as occurred in the 20th century; some devices were recalled.
Nerve palsy Post operative
sciatic nerve palsy is another possible complication. The frequency of this complication is low.
Femoral nerve palsy is another, but much rarer, complication. Both of these may resolve over time, but the healing process is slow. Patients with pre-existing nerve injury are at greater risk of experiencing this complication and are also slower to recover.
Chronic pain A few patients who have had a hip replacement suffer chronic pain after the surgery. Groin pain can develop if the muscle that raises the hip (
iliopsoas) rubs against the edge of the acetabular cup. Bursitis can develop at the trochanter where a surgical scar crosses the bone, or if the femoral component used pushes the leg out to the side too far. Also some patients can experience pain in cold or damp weather. Incision made in the front of the hip (anterior approach) can cut a nerve running down the thigh leading to numbness in the thigh and occasionally chronic pain at the point where the nerve was cut (a neuroma).
Death The rate of
perioperative mortality for elective hip replacements is significantly less than 1%.
Metal-on-metal hip implant failure By 2010, reports in the orthopaedic literature increasingly cited the problem of early failure of metal-on-metal prostheses in a small percentage of patients. Failures may have related to the release of minute metallic particles or metal ions from
wear on the implants, causing pain and disability severe enough to require revision surgery in 1–3% of patients. Design deficits of some prothesis models, especially with heat-treated alloys and a lack of specialized surgical experience, accounted for most of the failures. In 2010, surgeons at medical centers such as the
Mayo Clinic reported curtailing their use of metal-on-metal implants by 80 percent over the previous year, in favor of those made from other materials, such as combinations of metal and plastic. The cause of these failures remains controversial, and may include both design factors, operative technique factors, and factors related to patient
immune response. In the United Kingdom, the
Medicines and Healthcare products Regulatory Agency commenced an annual monitoring regime for metal-on-metal hip replacement patients from May 2010. Data which are shown in The Australian Orthopaedic Association's 2008 National
Joint replacement registry, a record of nearly every hip implanted in that country over the previous 10 years, tracked 6,773 BHR (Birmingham Hip Resurfacing) hips and found that less than 0.33% may have been revised due to the patient's reaction to the metal component. Other, similar, metal-on-metal designs have not fared as well, with some reports showing that 76–100% of people with these metal-on-metal implants with aseptic implant failures and needing revision surgery also had histological evidence of inflammation, accompanied by extensive
lymphocyte infiltrates characteristic of
delayed-type hypersensitivity reactions. It is not clear to what extent this phenomenon negatively affects orthopedic implant patients. However, for patients presenting with signs of allergic reaction, testing for sensitivity should be conducted. Removal of the device should be considered, since removal may alleviate the symptoms. Patients who have allergic reactions to
alloy jewelry are more likely to have reactions to orthopedic implants. There is increasing awareness of the phenomenon of metal sensitivity, and many surgeons now take this into account when planning which implant is optimal for each patient. On March 12, 2012,
The Lancet published a study, based on data from the National Joint Registry of England and Wales, finding that metal-on-metal hip implants failed at much higher rates than other types of hip implants, and calling for a ban on all metal-on-metal hip prostheses. The analysis of 402,051 hip replacements showed that 6.2% of metal-on-metal hip implants had failed within five years, compared to 1.7% of metal-on-plastic and 2.3% of ceramic-on-ceramic hip implants. Each increase in head size of metal-on-metal hip implants was associated with a 2% increase in failure rate. Surgeons of the British Hip Society recommended that large head metal-on-metal implants should no longer be implanted. On February 10, 2011, the U.S.
FDA issued an advisory on metal-on-metal hip implants, stating it was continuing to gather and review all available information about metal-on-metal hip systems. On June 27–28, 2012, an advisory panel met to decide whether to impose new standards, taking into account findings of the study in
The Lancet. No new standards, such as routine checking of blood levels of metal ions, were set, but guidance was updated. The U.S. FDA does not require hip implants to be tested in clinical trials before they can be sold in the U.S. Instead, companies making new hip implants only need to prove that they are "substantially equivalent" to other hip implants already on the market. The exception is metal-on-metal implants, which were not tested in clinical trials, but, due to the high revision rate of metal-on-metal hips, the FDA has stated that, in the future, clinical trials will be required for approval, and that post-market studies will be required to keep metal-on-metal hip implants on the market. ==Modern process==